News
Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback